Compare JJSF & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | DVAX |
|---|---|---|
| Founded | 1971 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | 2004 |
| Metric | JJSF | DVAX |
|---|---|---|
| Price | $96.79 | $15.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $138.33 | $26.50 |
| AVG Volume (30 Days) | 206.0K | ★ 5.6M |
| Earning Date | 02-02-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.36 | N/A |
| Revenue | ★ $1,583,233,000.00 | $330,514,000.00 |
| Revenue This Year | $4.28 | $24.63 |
| Revenue Next Year | $2.24 | $15.85 |
| P/E Ratio | $28.90 | ★ N/A |
| Revenue Growth | 0.54 | ★ 26.73 |
| 52 Week Low | $80.67 | $9.20 |
| 52 Week High | $146.67 | $15.73 |
| Indicator | JJSF | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 62.96 | 85.75 |
| Support Level | $92.94 | $15.57 |
| Resistance Level | $98.43 | $15.73 |
| Average True Range (ATR) | 2.29 | 0.06 |
| MACD | 0.67 | -0.05 |
| Stochastic Oscillator | 82.86 | 70.83 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.